Indication
Treatment of acute hepatic porphyria (AHP) in adults and adolescents aged 12 years and older.
Loading your page…
Loading your page…
Porphyrias, Hepatic
Marketing Authorisation Holder: Alnylam Netherlands B.V.
EMA Authorisation: 02/03/2020
INN: givosiran
AI Drug & Interaction Analysis
Free account required
Ask Osler about Givlaari: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.